Press Releases
Half yearly report to 31 March 2020
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces its unaudited interim results for the six months ended 31 March 2020. Financial highlights: · Reported revenues of £4. 6 million; 33. 0% growth on H1 2019 (2019: £3. 4 million) · Strong gross margin at 66. 5% (2019: 66.
Read more
Support free cabs for NHS workers
To help relieve the pressure on NHS staff travelling to and from hospitals minicabit , a nationwide cab booking service, will provide through up to 800 cab companies free cab services to NHS staff. They will engage 25,000 drivers and make as many available as possible. THE NEED IS URGENT.
Read more
£10.5m contract win, trading update for the period ended 31 March 2020, and the potential impact of COVID-19
New contract win: IXICO plc (AIM: IXI) is pleased to announce today the signing of a substantial new contract for a late-phase open label study in Huntington's disease (HD). The four-year contract runs to 2024 with a total value of £10.
Read more
IXICO's Response to Novel Coronavirus (COVID-19) - Update
20 March 2020: IXICO Response to Novel Coronavirus (COVID-19) - Update Dear Valued Client and Partners Earlier this week the UK government updated its guidance in response to the COVID-19 pandemic (as of 16 March), to escalate social distancing measures and minimise the need for non-essential travel.
Read more
Webinar Launch: Optimization of Tau PET Imaging for Alzheimer’s Clinical Development
IXICO will be hosting a webinar entitled 'Optimization of Tau PET Imaging for Alzheimer’s Clinical Development' on Friday 24th April at 10am EDT (NA) / 3pm BST (UK) / 4pm CEST (EU-Central), with our guest speaker Victor L. Villemagne from The University of Melbourne.
Read more
IXICO's Response to Novel Coronavirus (COVID-19)
It is not possible to predict the spread of COVID-19, nor the actions that may be taken by national governments to contain the spread of disease.
Read more
IXICO announces an expanded contract for its imaging services with Vaccinex
Supports Vaccinex's diversification into clinical development of pepinemab for Alzheimer's disease We are delighted to announce an award of a contract to provide imaging services for Vaccinex Inc. 's planned Phase Ib/IIa trial of pepinemab, a potential treatment of Alzheimer's disease (AD).
Read more
IXICO to present AI segmentation research at Huntington's Disease Therapeutics Conference
We will be presenting a scientific poster on enhancing imaging analysis accuracy for Huntington's Disease (HD) by comparing two types of Artificial Intelligence (AI) techniques at the CHDI Foundation 15th Annual 2020 Huntington's Disease Therapeutics Conference held from 24 - 27 February, 2020 in Palm Springs, California, USA.
Read more1-8 of 24 results